Case-Based
Medicine Teaching Series
Gastrointestinal Motility Disorders: Part 2 of 4
DATE
OF ORIGINAL RELEASE: July 2005
VALID FOR CME CREDIT THROUGH: July 31, 2006
NEEDS
STATEMENT
Functional gastrointestinal (GI) disorders include an array of dysfunctions
that occur in both the lower and the upper GI tract. These disordersincluding
irritable bowel syndrome, certain types of chronic constipation, non-ulcer
dyspepsia, and nonerosive esophageal reflux diseasehave many overlapping
symptoms that can often confound and confuse diagnosis. Furthermore, patients
with functional GI motility disorders often have other comorbid conditions,
such as fibromyalgia and psychiatric disorders that can further complicate
and delay accurate diagnosis. Recently, steps have been taken to better
equip physicians with the necessary tools to properly diagnose functional
GI disorders. New research has greatly enhanced our understanding of the
pathophysiology of functional GI disorders, which is contributing to the
development of novel and unique agents that address the multiple symptoms
that often characterize these disorders.
TARGET
AUDIENCE
This activity is intended for
gastroenterologists and other professionals involved in the care of individuals
with gastrointestinal motility disorders.
OBJECTIVES
At the conclusion
of this activity, participants should be able to:
- Identify the
appropriate use of criteria in diagnosing GI motility disorders.
- Compare and contrast
the symptoms of diffuse esophageal spasm, dumping syndrome, and Hirschsprung's
disease.
- Discuss the different tests
used to diagnose and treat diffuse esophageal spasm and dumping syndrome.
- Discuss the unique
characteristics and physiologic features associated with Hirschsprung's
disease.
- Describe the treatment
challenges commonly encountered with functional GI motility disorders.
ACCREDITATION
STATEMENT
Physicians:
This
activity has been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical
Education (ACCME) through the joint sponsorship of CME Consultants, Inc.,
and McMahon Publishing Group. CME Consultants, Inc., is accredited by
the ACCME to provide continuing medical education for physicians. In order
to receive credit for this program, each participant must complete the
evaluation form and answer sheet. CME Consultants, Inc., designates this
educational activity for a maximum of 1 Category 1 credit toward the AMA
Physician's Recognition Award. Each physician should claim only those
credits that he/she actually spent in the activity. Any questions regarding the accreditation of this CME activity should
be directed to CME Consultants,
Inc.
Pharmacists:
CME Consultants, Inc.,
has been accredited as a provider of continuing education for pharmacists
by the Accreditation Council for Pharmacy Education (ACPE). In order to
receive credit for this activity, all participants must complete an evaluation
form and post-test certifying their completion of this activity. This
activity has been accredited for 1 contact hour (0.1 CEU). There will
be no fee for this activity. ACPE #309-999-05-006-H01. Initial Release
Date: 7/1/05. Planned Expiration Date: 7/31/06.
Nurses:
CME Consultants, Inc.,
is accredited as a provider of continuing nursing education by the American
Nurses Credentialing Center's Commission on Accreditation and designates
this activity for 1.2 contact hours. In order to receive credit for this
activity, all participants must complete an evaluation form and post-test
certifying their completion of this activity.
ESTIMATED
TIME TO COMPLETE
This activity should take approximately 60 minutes, including completion
of the CME post-test and evaluation form.
METHOD
OF PARTICIPATION
This activity should
take approximately 1 hour to complete. The participant should, in order,
read the objectives and monograph, answer the 10-question, multiple-choice
online post-test, and complete the online evaluation. The evaluation form
provides each participant with the opportunity to comment on the quality
of the instructional process, the perception of enhanced professional
effectiveness, the perception of commercial bias, and his/her views on
future educational needs. To receive credit for this activity, follow
the post-test instructions. A score of at least 70% is required to receive
credit for this course. One retake is allowed. There is no fee associated
with this activity. This credit will be valid through July 31, 2006. No
credit will be given after this date.
FACULTY
Series Editor
Brian Lacy, PhD, MD
Associate Professor of Medicine
Department of Medicine, Division of Gastroenterology
Dartmouth–Hitchcock Medical Center
Lebanon, New Hampshire
Contributing
Faculty
Joshua DeSipio, MD
Gastroenterology Fellow
Temple University Health Sciences Center
Philadelphia, Pennsylvania
Amy Foxx-Orenstein, DO, FACG
Associate Professor of Medicine
Mayo Clinic Rochester
Rochester, Minnesota
William Hasler, MD
Associate Professor of Internal Medicine
Division of Gastroenterology
University of Michigan Hospital
Ann Arbor, Michigan
Henry Parkman, MD
Professor of Medicine
Director of GI Motility Laboratory
Temple University
Health Sciences Center
Philadelphia, Pennsylvania
DISCLOSURE
STATEMENT
In direct response to the September
2004 ACCME Standards for Commercial Support, CME Consultants, Inc. issued
a conflict of interest policy dated January 2, 2005. The policy states
that the disclosure of potential financial conflicts of interest within
the last 12 months must be made and resolved prior to date of the CME/CE
activity where commercial support grants are to be used to fund the activity.
The following conflicts have been managed and resolved through CME Consultants,
Inc.’s Independent Review Committee. Our intent is to assist learners
in assessing the potential for bias in information that is presented during
the CME/CE activity.
The faculty is also aware it is their responsibility to inform the audience
if discussion of any non–FDA-approved uses of pharmaceutical, medical
equipment, prostheses, etc. will be included in their presentation.
FACULTY
DISCLOSURE STATEMENT
Joshua DeSipio, MD, has nothing to disclose.
Amy Foxx-Orenstein, DO, FACG, is a member of the advisory
board of Novartis. She is also a member of the speakers' bureau of Pri-Med.
William Hasler, MD, is a member of the speakers' bureaus
of GlaxoSmithKline, Novartis, and Solvay. He is a consultant for Novartis.
Brian Lacy, PhD, MD, has received research support from
AstraZeneca, GlaxoSmithKline, and Novartis.
Henry Parkman, MD, has nothing to disclose.
FDA DISCLOSURE
STATEMENT
The contents of some CME activities may contain discussions of nonapproved
or off-label uses of some of the agents mentioned. Please consult the
prescribing information for full disclosure of approved uses.
This educational activity includes discussion of published and/or investigational
uses of acarbose, alosetron, botulinum toxin, calcium channel blockers,
nitrates, octreotide, and omeprazole.
SOFTWARE
REQUIREMENTS
Internet
Explorer (v5.5 or greater) or Netscape
(v7.02 or greater)
Adobe
Acrobat Reader
Internet Explorer not supported on the Macintosh.
Windows 98 SE or above.
Jointly
sponsored by CME Consultants, Inc., and McMahon Publishing Group.

Pharmacists
Click Here
Nurses
Click Here
CME Consultants, Inc. has
a policy that informs the learner of its Privacy and Confidentiality information
as it relates to Internet-based CME activities. Go to www.cmeconsultantsinc.com
to review in its entirety.
©CME
Consultants, Inc. 2005. All rights reserved. No part of this publication
may be reproduced, stored in a retrieval system, or transmitted in any
form or means without prior permission, except for the purposes of references
and comment.
Although great care has been
taken in compiling and checking the information contained in this Bulletin
to ensure accuracy, neither the publisher nor CME Consultants, Inc. shall
be liable for the accuracy of the information or for any errors, omissions,
or inaccuracies in this publication.
|